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Introduction {#sec1}
============

Paget disease of bone (PDB \[MIM: [602080](602080){#intref0010}\]) is a common metabolic bone disorder characterized by focal areas of increased osteoclastic bone resorption coupled with a disorganized increase in osteoblastic bone formation.[@bib1], [@bib2], [@bib3] These abnormalities disrupt normal bone architecture and result in enlarged and deformed bones in one (monostotic form) or more (polyostotic form) regions of the skeleton. In less than 1% of cases, pagetic tissue might undergo neoplastic transformation, resulting in osteosarcoma and, less frequently, in giant cell tumor of bone (GCT); only 117 cases of GCT associated with PDB (GCT/PDB) are reported in the literature.[@bib4], [@bib5], [@bib6], [@bib7] These tumors arise in bones affected by PDB, and can appear as multifocal lesions. Despite the fact that familial clustering has been described in PDB-affected individuals with GCT, the underlying genetic alterations and the molecular basis of tumorigenesis in pagetic tissue remain to be defined.

Genetic factors are important in the pathogenesis of PDB, and in many affected families, inheritance has been described as autosomal dominant. Since 2002, mutations in *SQSTM1* (MIM: [601530](601530){#intref0015}) have been identified in up to 40% and 10% of individuals with familial and sporadic PDB, respectively.[@bib8], [@bib9] Genome-wide association studies have suggested additional predisposition loci in individuals with PDB who are negative for *SQSTM1* mutations.[@bib10], [@bib11] Recently, we reported on a large family with 14 members affected by PDB, four of whom developed GCT at single or multiple pagetic skeletal sites.[@bib12] We excluded the presence of mutations in *SQSTM1* or in other genes known to be associated with PDB-related syndromes (*TNFRSF11A* \[MIM: [603499](603499){#intref0020}\], *TNFRSF11B* \[MIM: [602643](602643){#intref0025}\], *VCP* \[MIM: [601023](601023){#intref0030}\], and identified multiple chromosomal regions, potentially housing the causative mutation.[@bib12], [@bib13] We now report the identification of a heterozygous missense mutation in *ZNF687* (MIM: 6010568) in all affected members of the family and in seven additional unrelated individuals with GCT/PDB. The same mutation (c.2810C\>G) and one additional mutation (c.725G\>T) in *ZNF687* (GenBank: [NM_020832.2](ncbi-n:NM_020832.2){#intref0035}) were also detected in two families and in some severe PDB cases (with earlier onset and an increased number of affected skeletal sites) from two cohorts of pagetic individuals with different genetic backgrounds and previously analyzed for *SQSTM1* mutations.[@bib14], [@bib15]

Subjects and Methods {#sec2}
====================

Subjects {#sec2.1}
--------

The pedigrees of familial PDB-affected individuals with GCT and the clinical features of the affected family members are provided in [Figure 1](#fig1){ref-type="fig"}A, [Table 1](#tbl1){ref-type="table"}, and [Table S1](#mmc1){ref-type="supplementary-material"}. A replication cohort of seven unrelated PDB individuals with a history of GCT degeneration was also included in the study ([Table 1](#tbl1){ref-type="table"}). Moreover, 30 additional families affected by PDB, 20 of which were negative for mutation screening of *SQSTM1* or other genes associated with PDB-related syndromes, were also tested for *ZNF687* mutations. Then, we extended the screening of *ZNF687* mutations to two separate cohorts of PDB-affected individuals of Italian (n = 628) and multiethnic American (n = 342) backgrounds; these cohorts were previously analyzed for *SQSTM1* mutations. Unaffected control individuals of Italian (n = 564) and North-American (n = 269) origins were also screened as a reference. Clinical characteristics of PDB-affected individuals and control individuals are shown in the Supplemental Data ([Table S2](#mmc1){ref-type="supplementary-material"}). The studies were approved by ethics review committees at the relevant institutions and all participants provided informed consent.

Whole-Exome Sequencing Strategy {#sec2.2}
-------------------------------

Genomic DNA samples from four family members belonging to the extended pedigree were tested with the NimbleGen SeqCap EZ ExomeTM capture kits (Roche), and the resultant fragments were sequenced on an Illumina GAIIx (Illumina) with 90 bp paired-end reads. Reads were obtained and aligned to the human reference genomic sequence (UCSC Genome Browser GRCh37/hg19) with MAQ7 and NextGENe software v.2.0. We adopted a prioritization scheme, described in [Table S3](#mmc1){ref-type="supplementary-material"}, to identify the pathogenic mutation in each individual, similar to the approach used in our recent study.[@bib16] First, in order to reduce the number of candidate variants, we excluded the variants registered in the dbSNP131 and in our four in-house exomes, derived from four individuals with unrelated diseases and whose genetic basis was identified in our previous studies.[@bib16], [@bib17] After filtering, we compared data from three affected individuals (V-4, V-18, and V-11) to obtain shared variants, and we excluded those present in the healthy subject (V-7), thus identifying 57 variations in 45 genes ([Table S4](#mmc1){ref-type="supplementary-material"}). Sanger sequencing allowed us to validate 21 out of these 57 variations.

Mutation Analysis of *ZNF687* {#sec2.3}
-----------------------------

We conducted mutation screening of all 9 exons of *ZNF687* and their intron-exon boundaries by using PCR followed by automated DNA sequencing. PCR reactions (25 μL) were performed with Taq DNA polymerase (1 U; Fermentas), 1× buffer, deoxynucleoside triphosphate (dNTP, 0.2 mM; Amersham), primers (0.5 μM), and DNA (100 ng). PCR conditions were as follows: initial denaturation at 94°C for 3 min, followed by 35 cycles of 94°C for 30 s, 30 s at annealing temperature, extension at 72°C for 45 s, and a final extension for 10 min at 72°C.

Samples were ExoSap-digested (Amersham) and sequenced with the Big Dye Terminator Ready Reaction Kit (Applied Biosystems). Sequencing reactions were performed with a 9700 Thermal Cycler (Applied Biosystems) for 25 cycles of 95°C for 10 s, 50°C for 5 s, and 60°C for 2 min. After sequencing, each reaction was column purified (Amersham) to remove excess dye terminators.

The sequencing of the products was performed with the ABI Prism 3710 Genetic Analyzer (Applied Biosystems).

Primers used for *ZNF687* amplification and sequencing are reported in [Table S5](#mmc1){ref-type="supplementary-material"}.

*ZNF687* Tissue Expression Pattern {#sec2.4}
----------------------------------

The tissue expression pattern of *ZNF687* was determined by real-time PCR ([Figure S3](#mmc1){ref-type="supplementary-material"}) with the Light-Cycler system DNA Engine Opticon 2 (Biorad) and was performed on total RNAs derived from human adult tissues that were purchased from Stratagene. Total RNA was reverse transcribed with a RevertAid RT kit (Thermo Scientific). qPCRs were performed with SYBR Select Master Mix for CFX (Applied Biosystems) on a Bio-Rad CFX Connect Real-Time System instrument. The *ZNF687* transcript primers used to evaluate *ZNF687* mRNA expression are reported in [Table S5](#mmc1){ref-type="supplementary-material"}. *HPRT* primers were used to normalize *ZNF687* expression ([Table S5](#mmc1){ref-type="supplementary-material"}). This experiment was carried out in triplicate.

Generation of Human Osteoclasts from PBMCs {#sec2.5}
------------------------------------------

Osteoclasts were generated in vitro, with peripheral blood mononuclear cells (PBMCs) from healthy volunteers and age- and sex-matched pagetic individuals. PBMCs were isolated from citrate blood samples by density-gradient centrifugation in Ficoll (Histopaque 1077 Human Lymphocyte, Sigma-Aldrich), washed in 1× PBS, and re-suspended in alpha-minimal essential medium (α-MEM) (Sigma-Aldrich, Life Science), containing 100 U/mL penicillin, 100 mg/mL streptomycin (Gibco), 2 mM L-glutamine (Life Technologies) and 10% heat-inactivated fetal bovine serum (FBS). PBMCs were cultured in 96-well plates (8 × 10^5^ cells per well) for RNA extraction, tartrate resistant acid phosphatase (TRAP) staining, and immunofluorescence. The cells were cultured in a humid atmosphere with 5% CO~2~ in α-MEM and, after overnight incubation, the cultures were supplemented with 20 ng/mL of macrophage colony-stimulating factor (M-CSF; PeproTech) and 30 ng/mL of soluble human recombinant RANK ligand (sRANKL; PeproTech) and cultured for 14 days. Total RNA extraction was performed with TRIzol Reagent (Sigma-Aldrich), according to the manufacturer's protocol. Total RNA reverse transcription and qPCR were performed as described above. *ZNF687* expression profile during in vitro human osteoclastogenesis was obtained with the primers reported in [Table S5](#mmc1){ref-type="supplementary-material"}.

At the end of the culture, cells were fixed for 20 min at room temperature with 4% paraformaldehyde (Sigma-Aldrich) and stained for TRAP activity with a 87A Sigma Acid Phosphatase, Leukocyte (TRAP) Kit (Sigma-Aldrich). The nuclei were counterstained with methyl green. Multinucleated TRAP-positive cells were considered to be differentiated osteoclasts and were counted under a Zeiss microscope. For immunofluorescence assay, the TRAP+ cells were washed several times in 1× PBS and then incubated with 0.1% Triton X-100 (EuroClone) for 10 min at 4°C. Then, the cells were washed several times with 1× PBS and incubated with Texas RedsX-phalloidin (Life Technologies) for 20 min. The nuclei were counterstained with DAPI. Slides were analyzed with a Zeiss Axioplan.

Generation of Human Osteoblasts from Molar Follicles {#sec2.6}
----------------------------------------------------

Normal human third-molar follicles were collected from tooth buds of healthy pediatric individuals, aged 8--12 years and who underwent extractions for orthodontics reasons, after obtaining informed consent from the parents of each individual. Dental follicles (DFs) were digested for 1 hr at 37°C in agitation in a solution of 3 mg/mL type I collagenase plus 4 mg/mL dispase (Gibco). Single-cell suspensions were obtained by passing the cells through a 70 μm BD Falcon strainer (Becton Dickinson). After filtration, single cell suspensions were seeded in a 25 cm^2^ culture flask and cultured in α-MEM supplemented with 5% FBS, 100 U/mL penicillin-G, 100 μg/mL streptomycin, and 0.25 μg/mL fungizone (Gibco). Flasks were incubated at 37°C and 5% CO~2~. For the induction of osteoblastic differentiation, the cells were grown in α-MEM supplemented with 2% FBS, 10^−8^ M dexamethasone, and 50 μg/mL ascorbic acid (Sigma-Aldrich). For in vitro mineralized nodule evaluation, we cultured them for 30 days in α-MEM, supplemented with 10 mM β -glycerophosphate (Sigma-Aldrich). Total RNA extraction was performed with TRIzol Reagent (Sigma-Aldrich), according to the manufacturer's protocol. One μg of total RNA was reverse transcribed as previously described. qPCRs were performed as previously described. *ZNF687* expression profile during in vitro human osteoblastogenesis was obtained with the primers reported in [Table S5](#mmc1){ref-type="supplementary-material"}.

Ethics Statement {#sec2.7}
----------------

Animal handling and experiments were legally accredited by the Portuguese Direcção Geral de Veterinária, and all the experimental procedures involving animals were performed according to the EU (Directive 86/609/CEE) and National (Portaria n° 1005/92 de 23 de Outubro; Portaria n° 466/95 de 17 de Maio; Portaria n° 1131/97 de 7 de Novembro) legislation for animal experimentation and welfare.

Fish Maintenance {#sec2.8}
----------------

Zebrafish eggs were obtained from natural spawning of in-house broodstock maintained in a ZebTec housing system (Tecniplast). Water parameters were maintained as follows: pH 7.6 ± 0.2, conductivity 700 mS, dissolved oxygen 7.8 mg/L, and photoperiod 14:10 hr light:dark. Fertilized eggs were maintained until hatching in 1 L water tanks at a density of 200 eggs/L and with 0.5 ppm of methylene blue to avoid fungi development. Hatched larvae were raised until 30 days post-fertilization (dpf) in 1 L water tanks at a density of 100 larvae/L, and 90% of the water was renewed every 2 days. Larvae from 5 to 10 dpf were fed twice a day with Artemia nauplii (AF strain INVE, 5--10 nauplii/mL) and from 8 to 30 dpf with Artemia metanauplii (EG strain INVE, 10 metanauplii/mL). Juveniles, adults, and broodstock were maintained in 10 L plastic tanks with recirculating fresh water at 28°C (Tecniplast ZebTEC) and fed twice a day with commercial dry food (Tetramin flake C) and once a day with Artemia metanauplii.

Larval and Tissue Sampling {#sec2.9}
--------------------------

Fish embryos and larvae were sampled at 1 (4 cells), 3 (1,000--2,000 cells), 16 (14 somites), 24, 32, 48, 72, and 96 hr post-fertilization (hpf), and 5, 7, 9, 15, 20, and 30 dpf. The amount of material sampled at each developmental stage was adapted to specimen size and included about 100 eggs for the earliest developmental stages and five *Danio rerio* specimens for early juveniles (30 dpf). Adult zebrafish tissues (eye, operculum, vertebra, gills, liver, kidney, spleen, ovary, and scales) were collected and pooled from three males and two females. All fish were anesthetized with a lethal dose of tricaine methanesulfonate (MS-222; Sigma-Aldrich) and washed with sterile distilled water before sampling. For fin and blastema recovery, 20 adult fish were anesthetized, as mentioned above, and washed with PBS. Fins were then amputated, washed in PBS, and pooled to obtain two biological replicates. 36 hr post-amputation (hpa), fish were re-anesthetized and the blastemas were recovered, washed with PBS, and pooled to obtain two biological replicates.

Specimens and tissues collected for gene-expression analysis were placed in ten volumes of TRI Reagent (Ambion) and stored at −80°C until processed.

*Danio rerio* RNA Extraction and qPCR {#sec2.10}
-------------------------------------

Total RNA was extracted from samples stored in TRI-Reagent, according to the manufacturer's instructions, and purified with a High Pure RNA Isolation Kit (Roche). RNA integrity was confirmed with an Experion Automated Electrophoresis System (Bio-Rad). Total RNA was reverse transcribed with M-MLV reverse transcriptase (Invitrogen), according to the manufacturer's protocol. qPCR was performed in triplicate with isoform-specific primers ([Table S5](#mmc1){ref-type="supplementary-material"}). Levels of gene expression were calculated with the ΔΔCt comparative method and normalized with housekeeping *rps18* ([Table S5](#mmc1){ref-type="supplementary-material"}).

Bioinformatic Predictions {#sec2.11}
-------------------------

The NLStradamus program was used to predict the nuclear localization site of ZNF687.[@bib18], [@bib19] The NetPhos 2.0 server was used to predict serine, threonine, and tyrosine phosphorylation sites in ZNF687.[@bib20]

Immortalization and Cell Culture of Lymphoblasts {#sec2.12}
------------------------------------------------

10 mL of blood were drawn from a peripheral vein, and lymphoblasts were isolated on a Ficoll-Diatrizoate density gradient (Ficoll-Paque; Pharmacia). B-lymphoblasts were immortalized by incubation with supernatant containing Epstein-Barr virus. After immortalization, B-lymphoblasts were grown for 10--14 days in RPMI 1640 medium (Gibco), supplemented with 2 mM L-glutamine, 100 U/mL penicillin, 100 mg/mL streptomycin (Gibco), and 20% FBS.

Cytoplasmic and Nuclear Protein Extraction from Lymphoblasts {#sec2.13}
------------------------------------------------------------

The cells were washed with cold PBS (2.7 mM KCl, 1.2 mM KH~2~PO~4~, 8.1 mM Na~2~HPO~4~, 138 mM NaCl \[pH 7.4\]) and cytoplasmic extraction was obtained in 100--1,000 μL of hypotonic buffer (10 mM Tris-HCl \[pH 7.5\], 2mM MgCl~2~, 10 mM CaCl~2~, 30 mM Sucrose, 1% NP40) and 1× proteinase inhibitor mixture (20 μg of 4-amidinophenyl-methanesulfonyl fluoride, 25 μg of antipain, 20 μg of aprotinin, 5 μg of nitobestatin, 20 μg of chymostatin, 25 μg of 3,4-dichloroisocoumarin, 50 μg of E-64, 10 μg of leupeptin, 10 μg of pepstatin A and 10 μg of phosphoramidon per mL, 50 μM bezamidine, 50 μM sodium metabisulfite). The lysis was performed with a syringe with a narrow-gauge (no. 27) hypodermic needle and was observed by the addition of a Trypan Blue solution. Then, the disrupted cells were centrifuged for 20 min at 10,000--11,000 rcf (relative centrifugal force). Nuclear extracts were sequentially obtained in 140 μL of extraction buffer (0.42 M NaCl, 0.2 mM EDTA, 25% Glycerol, 1% NP40) and 1× proteinase inhibitor mixture. Crude nuclei were shaken gently and then incubated for 10 min on ice. Finally, nuclear extracts were obtained through centrifugation for 5 min at 20,000--21,000 rcf.

Western Blot Analysis for ZNF687 Cytoplasmic and Nuclear Localization {#sec2.14}
---------------------------------------------------------------------

Proteins were denatured by being boiled in sample buffer, separated on 8% SDS-PAGE, transferred onto a Immun-Blot PVDF Membrane For Protein Blotting (Bio-Rad), and blocked for 1 hr in 5% non-fat powdered milk in TBS-T (10 mM Tris-HCl \[pH 7.5\], 100 mM, NaCl, 0.1% \[v/v\] Tween-20). Rabbit polyclonal anti-ZNF687 antibody ab105544 (1:500 diluted in TBS-T; Abcam), α Tubulin (B-7) sc-5286 (1:500 diluited in TBS-T; Santa Cruz), and anti-RNA polymerase II ab815 (1:1,000 diluted in TBS-T; Abcam,) were used for protein detection. Peroxidase-conjugated goat anti-rabbit (1:1,000 for ZNF687) and anti-mouse (1:1,000 diluted in TBS-T for α tubulin and 1:2,000 diluted in TBS-T for RNA polymerase II; Bio-Rad) were used as secondary antibodies. Western blot assays were quantified with the ImageJ program.

RNA Extraction from Peripheral Blood of Pagetic Individuals {#sec2.15}
-----------------------------------------------------------

Venous blood derived from healthy volunteers and pagetic individuals (age- and sex-matched) was collected in a Tempus Blood RNA tube (Applied Biosystems) and immediately incubated at room temperature for 24 hr. RNA was extracted with a Tempus Spin RNA Isolation Reagent Kit (Applied Biosystems), and its quality was determined by a NANOD 1000 v.3.7.1 spectrophotometer (Thermo Scientific). Total RNA was reverse transcribed with RevertAid RT kit (Thermo Scientific) and qPCR was performed with the primers reported in [Table S5](#mmc1){ref-type="supplementary-material"}. The experiment was carried out in triplicate.

GCT Tumor Tissues {#sec2.16}
-----------------

The GCT/PDB tissue samples were obtained from surgically removed tumors, frozen in liquid nitrogen, and stored at −80°C. Total RNA was extracted from five frozen tumor tissues with TRIzol Reagent (Sigma-Aldrich), according to the manufacturer's protocol. Total RNA was reverse transcribed as previously mentioned, and qPCRs were performed in triplicate with the primers reported in [Table S5](#mmc1){ref-type="supplementary-material"}.

Immunohistochemistry Assay {#sec2.17}
--------------------------

ZNF687 immunohistochemical analysis was performed on GCT paraffin-embedded microsections. H&E-stained slides were carefully reviewed, and the diagnosis of GCT/PDB was confirmed. Several sections of GCT/PDB tissue served as control tissue. A Dako LSAB 2 System HRP Kit (Universal Dako Labeled Streptavidin Biotin 2 System Horseradish Peroxidase) was used on formalin-fixed, paraffin-embedded material from primary tumors. Sections (5 μm thick) were deparaffinized in xylene and rehydrated in graded alcohols and water and the endogenous peroxidase was blocked by treating the sections with 0.3% H~2~O~2~ for 5 min at room temperature. Microwave pre-treatment was used to reveal the antigens to reduce nonspecific binding. The sections were incubated with blocking serum for 15 min, then at 4°C overnight with goat polyclonal anti-ZNF687 antibody (E-20 sc-324734; Santa Cruz) at the dilution 1:100. The sections were then incubated with the biotinylated secondary antibody and subsequently with ABC (avidin-biotin-peroxidase complex; Biomeda). The staining was developed in DAB (3,3′-Diaminobenzidine), and the nuclei were counterstained with hematoxylin. Positive controls were included for each antibody and negative controls were prepared without the incubation with the primary antibody. The staining was scored for intensity (0 = no expression, 1 = weak to moderate expression, 2 = strong expression) by two different investigators and for the percentage of positive cells (0 ≤ 10%, 1 = 10%--25%, 2 = 26%--50%, 3 ≥ 50%). Cut-off levels for the sum of scores were applied as for negative cases: 1--3 for weakly positive and 4--5 for moderately to strongly positive, which is considered protein overproduction.

Results {#sec3}
=======

Identification of *ZNF687* Mutations in GCT/PDB {#sec3.1}
-----------------------------------------------

The pedigrees of familial PDB individuals with GCT and the clinical features of the affected family members are provided in [Figure 1](#fig1){ref-type="fig"}A, [Table 1](#tbl1){ref-type="table"}, and [Table S1](#mmc1){ref-type="supplementary-material"}. Considering the high number of meiotic events in this extended pedigree, which reduces the number of candidate variants, we performed whole-exome sequencing of three affected PDB individuals (V-4, V-18, and V-11), two of whom had recurrent GCT, and one healthy subject (V-7) from family 1. We adopted a prioritization scheme, described in [Table S3](#mmc1){ref-type="supplementary-material"}, to identify the pathogenic mutation in each individual, similar to the approach used in our recent study.[@bib16] After excluding common SNPs and variants registered in the dbSNP131 and in our four in-house exomes (which are derived from four individuals with other diseases not related to bone metabolism, such as focal segmental glomerulosclerosis \[MIM: [603278](603278){#intref0040}\] and congenital fiber type disproportion \[MIM: [255310](255310){#intref0045}\]), we identified 21 candidate variants ([Tables S3](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}). Only one showed precise co-segregation with the disease phenotype in the family: the c.2810C\>G heterozygous change in exon six of *ZNF687*, which causes the p.Pro937Arg amino acid change ([Figure 1](#fig1){ref-type="fig"}B). *ZNF687* is localized on chromosome 1 (1q21.3), in one of the linkage candidate regions described in our previous report ([Figure S1](#mmc1){ref-type="supplementary-material"}).[@bib12]

Although its function has been poorly investigated, it is known that ZNF687, together with ZMYND8 and ZNF592, is part of the recently described transcriptional regulator complex Z3.[@bib21]

The proline residue at the 937 position of ZNF687 is highly conserved in mammals ([Figure 1](#fig1){ref-type="fig"}C). The c.2810C\>G mutation was not identified in a cohort of 564 unrelated healthy control individuals from the same geographical origin. Sanger sequencing confirmed the presence of the same c.2810C\>G mutation (founder mutation) in all affected members of family 1, but not in unaffected members. Moreover, the same mutation was detected in seven additional unrelated individuals with PDB complicated with GCT ([Figure S4](#mmc1){ref-type="supplementary-material"}). Four of these individuals were from the same circumscribed area of Southern Italy as family 1, and three were North-American individuals of European descent.[@bib14], [@bib15], [@bib22] In order to verify the hypothesis of a common ancestral chromosome among these GCT/PDB cases, we analyzed the segregation of rare variants in genes surrounding the *ZNF687* mutation, identifying, in all but one, identical variants for *SV2A* (MIM: [185860](185860){#intref0050}), *SETDB1* (MIM: [604396](604396){#intref0055}), *ZNF687*, and *HRNR* (MIM: [616293](616293){#intref0060}). This haplotype was not observed in any of the 564 control individuals of the same ethnic origin, suggesting that the c.2810C\>G mutation originated from a unique haplotype and segregated in all but one of the GCT/PDB-affected individuals tested in this study ([Figure 1](#fig1){ref-type="fig"}D). The occurrence of the c.2810C\>G mutation on a different haplotype in one individual (individual GCT/PDB6) provides the genetic evidence that this mutation is necessary and sufficient for GCT/PDB phenotype development.

Identification of *ZNF687* Mutations in Individuals with Severe PDB {#sec3.2}
-------------------------------------------------------------------

To determine the role of *ZNF687* in PDB-affected individuals without neoplastic transformation, we first analyzed the entire coding region of the gene in 30 additional PDB probands, 20 of whom were negative for *SQSTM1* mutations, as well as for mutations in other genes associated with PDB-related syndromes. Each of the analyzed probands had at least another family member with PDB, showing vertical transmission, which is consistent with the autosomal-dominant inheritance pattern of the disease. Mutation analysis identified the c.2810C\>G mutation in one proband (II-1, family 2) ([Figure 1](#fig1){ref-type="fig"}A) and a new mutation, c.725G\>T (p.Ser242Ile), in exon 2 of *ZNF687* in a different proband (family 3) ([Figure 2](#fig2){ref-type="fig"}A). The c.2810C\>G mutation segregated with the disease phenotype in family 2; it was detected in the affected relative (II-3) but not in his healthy brother (II-2). The proband (II-6) and all affected siblings (II-1 and II-3) of family 3 were heterozygous for the *ZNF687* c.725G\>T missense mutation. This mutation was not detected in the three unaffected family members (II-2, II-4, and II-5) of family 3 ([Figures 2](#fig2){ref-type="fig"}A and 2B) and was not reported in the 1000 Genome and ExAC databases. The serine at the 242 position of ZNF687 is highly conserved in all species ([Figure 2](#fig2){ref-type="fig"}C), and the p.Ser242Ile change was predicted in silico (by SIFT, PolyPhen, PMut, and Align GVGD) to be highly pathogenic, suggesting a causative role. Computational analysis strongly suggested Ser242 to be an important phosphorylation site (score of 0.996 in NetPhos prediction).[@bib20] Subsequently, both the c.2810C\>G and c.725G\>T mutations were screened by TaqMan assay in two cohorts of PDB-affected individuals of different ethnicity. The c.2810C\>G mutation was found in two out of 615 Italian individuals with PDB and two out of 339 individuals from a multiethnic North-American PDB-affected cohort. Both mutations were absent in chromosome samples from the two cohorts of control individuals of Italian and North-American origin. All these data suggest that *ZNF687* mutations are present in a subset of individuals with familial PDB and more rarely in individuals with sporadic PDB. Moreover, most individuals with *ZNF687* mutations showed a severe form of PDB, with an earlier onset and greater number of affected skeletal sites than individuals with or without *SQSTM1* mutations ([Table 1](#tbl1){ref-type="table"} and [Figure 2](#fig2){ref-type="fig"}D).

Role of ZNF687 in Bone Metabolism {#sec3.3}
---------------------------------

The expression profile of *ZNF687* was evidenced by real-time PCR in all examined adult human tissues, including bone ([Figure S3](#mmc1){ref-type="supplementary-material"}). To investigate *ZNF687* mRNA expression during osteoclast formation, PBMCs from healthy volunteers were induced to osteoclastogenesis by treatment with M-CSF and sRANKL. Osteoclastogenesis was assessed by TRAP staining as described in [Subjects and Methods](#sec2){ref-type="sec"}. Our results showed that, after treatment with M-CSF and RANKL, *ZNF687* expression was significantly increased ([Figure 3](#fig3){ref-type="fig"}A). Furthermore, given that GCT derives from the uncontrolled proliferation of mesenchymal stromal cells committed toward osteoblastic lineage, we also evaluated *ZNF687* expression during osteoblastogenesis. As expected, *ZNF687* mRNA expression was higher in differentiated osteoblasts than in their undifferentiated precursors ([Figure 3](#fig3){ref-type="fig"}B). Collectively, these data indicate that *ZNF687* plays a role in bone metabolism and that it is highly expressed during osteoclast and osteoblast differentiation. To further verify this, we evaluated the expression levels of the two zebrafish orthologs (*ZNF687a* and *ZNF687b*) during *Danio rerio* development and during tissue regeneration (blastema), after caudal fin amputation. Both genes showed high expression levels during the regeneration of the caudal fin ([Figures 3](#fig3){ref-type="fig"}C and 3D), suggesting a possible role in cell proliferation and differentiation. Consistent with this observation, both genes appeared to be maternally inherited and highly expressed in the initial stages of zebrafish development. Interestingly, expression of *ZNF687a* increased again between 24 hr and 5 dpf and after 20 dpf, when hematopoiesis and osteoclastogenesis are known to occur in zebrafish ([Figure 3](#fig3){ref-type="fig"}E).[@bib23] Accordingly, *ZNF687a* was also highly expressed in adult kidney and spleen tissues, the major organs for proliferation and differentiation of the hematopoietic cells, including osteoclast precursors ([Figure S4](#mmc1){ref-type="supplementary-material"}).

Functional Consequences of *ZNF687* Mutation {#sec3.4}
--------------------------------------------

Bioinformatic analysis suggested that ZNF687 contains a strong nuclear localization signal (NLS) sequence between amino acids 938 and 954 ([Figure 3](#fig3){ref-type="fig"}F). The substitution of the arginine at the 937 position generates a stronger NLS that could enhance ZNF687 nuclear import. Therefore, we performed cellular protein fractionation analysis followed by Western blotting by using anti-ZNF687 antibody. Our analysis revealed ZNF687 to be less prominent in the cytoplasmic fraction in lymphoblastic cell lines derived from PDB-affected individuals with c.2810C\>G mutation than in those derived from control individuals ([Figures 3](#fig3){ref-type="fig"}G and 3H). We also found a parallel increase of ZNF687 in the nuclear fraction, suggesting that c.2810C\>G acts as gain-of-function mutation, altering the nuclear-cytoplasmic balance of ZNF687, thus leading to enhanced availability of this transcription factor in the nucleus. To directly test the causal link between the c.2810C\>G mutation in *ZNF687* and the osteoclast differentiation process, human PBMCs, derived from five PDB-affected individuals carrying the c.2810C\>G mutation, were differentiated into osteoclasts in the presence of sRANKL and M-CSF cytokines. Interestingly, osteoclasts cultured from these individuals showed a greater number of nuclei ([Figures 3](#fig3){ref-type="fig"}I--3J) as well as a larger surface area ([Figures 3](#fig3){ref-type="fig"}I and 3K) than did those from the control individuals, both features being peculiar for pagetic osteoclasts.

Increased *ZNF687* Expression in PDB-Affected Individuals {#sec3.5}
---------------------------------------------------------

Given that PDB is a disease of the osteoclast and *ZNF687* is upregulated during osteoclastogenesis, we evaluated *ZNF687* expression in PDB-affected individuals with different genetic backgrounds. Using real-time PCR, we assessed the expression level of *ZNF687* in PBMCs from six PDB-affected individuals without a *SQSTM1* mutation, five PDB-affected individuals with a *SQSTM1* mutation, five PDB-affected individuals with a *ZNF687* mutation, and three healthy subjects. Of interest, *ZNF687* expression levels were significantly higher in PDB-affected individuals with (3-fold) or without (2-fold) an *SQSTM1* mutation than in the control individuals ([Figure 4](#fig4){ref-type="fig"}A and [Figure S5](#mmc1){ref-type="supplementary-material"}). Moreover, a larger increase (5-fold) was observed in PDB-affected individuals exhibiting the c.2810C\>G mutation in *ZNF687* ([Figure 4](#fig4){ref-type="fig"}A and [Figure S5](#mmc1){ref-type="supplementary-material"}). These results suggest that *ZNF687* is involved in PDB pathogenesis regardless of the genetic background of PDB-affected individuals. Its expression profile remarkably correlates with the clinical severity of the disease. To further clarify *ZNF687* involvement in PDB pathogenesis, we first analyzed the ChIPBase database, an integrated platform for decoding transcription factor binding sites (including 11 independent ChIP-seq experiments of NFkB transcription factor).[@bib24] Interestingly, in all experiments, *ZNF687* was detected as a genomic target of NFkB in its putative promoter ([Figure 4](#fig4){ref-type="fig"}B). Similar to *ZNF687*, *ZMYND8* (MIM: [615713](615713){#intref0065}) and *ZNF592* (MIM: [613624](613624){#intref0070}), the other two partners of ZNF687 in the Z3 complex formation, are regulated by NFkB transcription factor, which binds their promoters (data not shown). Next, we evaluated *ZNF687* expression in tumor tissues derived from five individuals with GCT/PDB. As expected, in comparison to expression in healthy bone marrow, a dramatic increase in *ZNF687* expression was observed in the RNAs extracted from tumor biopsies of these individuals, confirming the pathological role of *ZNF687*, whose expression resulted from the c.2810C\>G mutation ([Figure 4](#fig4){ref-type="fig"}C). These data were reinforced by immunohistochemistry assays performed on tumor sections of the same GCT/PDB-affected individuals, in which we observed stronger ZNF687 staining in the pathological giant cells than in the stromal cells, in comparison to the negative section ([Figures 4](#fig4){ref-type="fig"}D and 4E).

Discussion {#sec4}
==========

Neoplastic transformation is a rare but serious complication of PDB, occurring in less than 1% of PDB-affected individuals. In a recent analysis of the cumulative survival curves of GCT occurring in individuals with or without PDB, we demonstrated that about half of PDB-affected individuals die within five years of the diagnosis of GCT, increasing to 80% after ten years.[@bib7] Here, we identify a pathogenic missense mutation in *ZNF687* (c.2810C\>G) in a large pagetic family characterized by an enhanced prevalence of GCT in up to 30% of affected members. The same mutation was also identified in all the tested unrelated individuals with PDB and GCT, as well as in one individual with PDB and a positive family history of GCT. Moreover, replication analysis identified the *ZNF687* c.2810C\>G mutation and a new *ZNF687* mutation (c.725G\>T) in two families with a clear family history for PDB. A further analysis of two large cohorts of unrelated PDB-affected individuals with different ethnic backgrounds identified the *ZNF687* c.2810C\>G mutation in 0.3% and 0.6% of cases, respectively. All individuals harboring mutations, except one, had polyostotic disorder with a significantly increased number of affected skeletal sites and an earlier onset of disease than PDB-affected individuals without the mutation, including PDB-affected individuals with the *SQSTM1* mutation. Taken together, these results indicate that mutations in *ZNF687* are associated with severe PDB, with a prevalence of 3/31 (10%) in our familial cases with a documented autosomal-dominant pattern of inheritance, whereas they occur rarely in non-familial disease. Given that all the individuals with PDB and GCT tested in this study were positive for the mutation, we conclude that this *ZNF687* mutation is responsible for severe PDB, sometimes complicated by GCT, in the presence of an impaired response to antiresorptive treatment.[@bib12]

*ZNF687* encodes a C2H2 zinc finger protein expressed in most tissues, including bone, that, together with ZMYND8 and ZNF592, is part of the transcriptional regulator complex Z3.[@bib21] Despite different C2H2 zinc finger proteins being identified as important regulators of skeletal development and maintenance, the role of *ZNF687* in bone metabolism has never been identified.[@bib25] Our in vitro and in vivo findings indicate that ZNF687 has bone regulatory properties. First, it is upregulated during osteoclast and osteoblast differentiation and is highly expressed during the regeneration of caudal fins in zebrafish, suggesting a role of this transcriptional co-regulator in bone cell proliferation and differentiation. Moreover, *ZNF687* has been shown to be overexpressed in all the tested PBMC samples derived from PDB-affected individuals, irrespective of the genetic defect, given that this gene is a downstream target of NFkB, allowing us to hypothesize the mechanism reported in [Figure 4](#fig4){ref-type="fig"}F.

The exact mechanism by which *ZNF687* mutations cause PDB and eventually GCT remains unknown. Because a stronger NLS was observed in the presence of the proline to arginine substitution at the 937 position, we hypothesize that the mutation acts as a gain of function, leading to the constitutive accumulation of ZNF687 in the nucleus, thus increasing the transcription of its downstream targets, which in turn might promote the development of the disorder. Remarkably, osteoclasts derived from PBMCs of PDB-affected individuals with the c.2810C\>G mutation in *ZNF687* were increased in size and contained more nuclei than normal osteoclasts, which are both features of osteoclasts isolated from pagetic tissue.[@bib1], [@bib2], [@bib3] These data suggest that the c.2810C\>G mutation might contribute to PDB susceptibility by affecting osteoclast phenotype.

In addition, considering that we identified the c.725G\>T mutation in familial individuals only affected by PDB, we hypothesized that c.725G\>T mutation is responsible for the onset of PDB, but not associated with GCT development. Therefore, we speculated that, differently from the c.2810C\>G mutation, the biological defect of c.725G\>T does not result in the neoplastic transformation of PDB tissue. Further functional studies are required to address this point as well as the biological difference with the c.2810C\>G mutation.

In conclusion, in this study we identified mutations in *ZNF687* as a monogenic cause of a severe, early-onset form of PDB, which is associated in some instances (c.2810C\>G mutation) with an increased likelihood of GCT. This evidence, together with our in vitro and in vivo experimental observations, emphasizes a previously unexpected role of *ZNF687* in bone metabolism. It would be of interest to determine the *ZNF687* role in other neoplastic conditions related to PDB, such as osteosarcoma, that, like GCT, are due to the malignant transformation of mesenchymal stromal cells.

Finally, a better characterization of the downstream pathways regulated by this transcriptional co-regulator in bone cells might be relevant for the identification of new therapeutic targets for PDB and other disorders of skeletal metabolism.
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=============
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![Identification of the c.2810C\>G Mutation in *ZNF687*\
(A) The pedigree of family 1, including 14 affected members, four of whom developed GCT at pagetic skeletal sites. Circles indicate female family members, and squares indicate male family members; slashes indicate that the family member is deceased. Family members with the GCT/PDB phenotype are indicated by a white dot in solid symbols, those with PDB are indicated by solid symbols, and those without any clinical symptoms are indicated by open symbols. + or -- signs indicate the presence or absence of the c.2810C\>G mutation. This panel also includes the pedigree for a different family (family 2) with the same c.2810C\>G mutation in *ZNF687*. The index individual with PDB (II-1) is indicated by an arrow.\
(B) The DNA sequence of a segment flanking c.2810C\>G in *ZNF687* from an unaffected family member (left) and a heterozygous GCT/PDB-affected individual (right). A single base substitution changes the non-mutant cytosine to guanine, leading to the substitution of proline (P) for arginine (R) at the 937 codon (indicated by a solid line).\
(C) A portion of the amino acid sequence of ZNF687 from diverse mammal species.\
(D) The ancestral haplotype with rare variants in *SV2A-rs149735232* (t minor-allele frequency = 1.5%), *SETDB1-rs138864506* (t minor-allele frequency = 0.1%), *ZNF687-rs142842127* (a minor-allele frequency = 0.2%), and *HRNR* (ta deletion, frequency not available), all of which are genes surrounding the c.2810C\>G mutation in *ZNF687*. For each variant, the position on chromosome 1 is indicated by arabic numerals.](gr1){#fig1}

![Identification of the c.725G\>T Mutation in *ZNF687*\
(A) The pedigree of family 3. The index individual is indicated by an arrow. Individuals with PDB are indicated by black symbols, and individuals without PDB are shown as unfilled symbols. Circles represent females, squares represent males, and slashes indicate deceased subjects.\
(B) The DNA sequence of a segment flanking c.725G\>T in *ZNF687* from an unaffected family member (left) and a heterozygous PDB-affected individual (right). A single base substitution changes the non-mutant guanine to thymine, leading to the substitution of serine (S) for isoleucine (I) at the 242 codon (indicated by a solid line).\
(C) The evolutive conservation of the 242 serine from rodents to humans.\
(D) The number of the affected skeletal sites (left) and the age of disease onset (right) across PDB-affected individuals with *ZNF687* mutations, PDB-affected individuals with *SQSTM1* mutations, and PDB-affected individuals without mutations in either gene. Genotype-phenotype correlations were tested by ANOVA with Bonferroni correction and reported as mean ratio ± SEM (not mutated, n = 615; mutated in *SQSTM1*, n = 78; mutated in *ZNF687*, n = 20). ^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.](gr2){#fig2}

![Expression and Functional Characterization of *ZNF687*\
(A and B) Expression analysis of *ZNF687* during human osteoclastogenesis (A) and human osteoblastogenesis (B). The data shown are representative of three independent experiments and were analyzed by Student's t test.\
(C and D) The scheme of caudal fin regeneration in zebrafish (*Danio rerio*) (C) and the expression of *ZNF687a* and *ZNF687b* (zebrafish orthologs) during this process (D).\
(E) *ZNF687a* and *ZNF687b* expression during *Danio rerio* development.\
(F) Bioinformatic prediction of the NLS in ZNF687 between amino acids 938 and 955 enhanced as a consequence of the substitution of arginine at the 937 position.\
(G) The expression of ZNF687 in nuclear- and cytoplasmic-extracts in lymphoblastic cell lines derived from affected individuals with the p.Pro937Arg change (PDB-affected individuals 1--4) in comparison to expression in those derived from healthy subjects (control individuals 1 and 2). ZNF687 antibody detected one band of about 135 kDa in the cytoplasm and two bands of about 100 and 135 kDa in the nucleus. Cytoplasm and nuclear extracts contained only minimal or no contamination (data not shown).\
(H) The quantifications of cytoplasmic and nuclear fractions.\
(I--K) The increased number of nuclei and the increased cellular area of osteoclasts derived from PDB subjects carrying the c.2810C\>G mutation compared to the controls.\
^∗^p \< 0.05; ^∗∗^p \< 0.01; ^∗∗∗^p \< 0.001.](gr3){#fig3}

![Upregulation of *ZNF687* in Peripheral Blood of PDB-Affected Subjects and in Tumor Tissues of GCT/PDB-Affected Individuals\
(A) The expression of *ZNF687* in peripheral blood from healthy subjects, PDB-affected individuals without *SQSTM1* or *ZNF687* mutations, PDB-affected individuals with an *SQSTM1* mutation, and PDB-affected individuals with a *ZNF687* mutation. ^∗^ = p \< 0.05; ^∗∗^ = p \< 0.01; ^∗∗∗^ = p \< 0.001.\
(B) NFkB binding sites on the *ZNF687* promoter region.\
(C) The expression profile of *ZNF687* in frozen tumor tissues from five GCT/PDB-affected individuals in comparison to the expression in tissue from healthy bone marrow.\
(D and E) ZNF687 expression on a tumor biopsy of a GCT/PDB-affected individual (D) in comparison to the tumor section derived from the same individual (E) without primary antibody (negative control).\
(F) A hypothetical model of ZNF687 involvement in the PDB molecular pathway.](gr4){#fig4}

###### 

Clinical Characteristics of Subjects with Familial and Sporadic PDB and Positive for *ZNF687* Mutations

  **Patient**                                 ***ZNF687* Mutation**   **Sex**   **Origin**         **GCT**   **PDB Onset (Age in Years)**   **No. of PDB sites**   **CHD**
  ------------------------------------------- ----------------------- --------- ------------------ --------- ------------------------------ ---------------------- ---------
  **Family 1**                                                                                                                                                     
  1.V-4                                       c.2810C\>G              M         Italian            yes       35                             12                     yes
  1.V-18                                      c.2810C\>G              M         Italian            no        41                             5                      yes
  1.V-11                                      c.2810C\>G              M         Italian            yes       41                             6                      yes
  **Family 2**                                                                                                                                                     
  2.II-1                                      c.2810C\>G              M         Italian            no        45                             4                      yes
  2.II-3                                      c.2810C\>G              F         Italian            no        26                             10                     no
  **Family 3**                                                                                                                                                     
  3.II-1                                      c.725G\>T               M         Italian            no        50                             4                      yes
  3.II-2                                      c.725G\>T               F         Italian            no        59                             2                      yes
  3.II-3                                      c.725G\>T               F         Italian            no        43                             3                      yes
  **Unrelated Individuals with GCT/PDB**                                                                                                                           
  GCT/PDB1                                    c.2810C\>G              M         Italian            yes       33                             7                      yes
  GCT/PDB2                                    c.2810C\>G              F         Italian-American   yes       NA                             2                      NA
  GCT/PDB3[a](#tblfn1){ref-type="table-fn"}   c.2810C\>G              F         Italian-American   no        NA                             2                      NA
  GCT/PDB4[b](#tblfn2){ref-type="table-fn"}   c.2810C\>G              F         Italian-American   yes       NA                             8                      NA
  GCT/PDB5                                    c.2810C\>G              M         Italian            yes       38                             7                      yes
  GCT/PDB6                                    c.2810C\>G              M         Italian            yes       53                             5                      NA
  GCT/PDB7                                    c.2810C\>G              M         Italian            yes       46                             5                      NA
  **Unrelated Individuals with PDB**                                                                                                                               
  PDB1                                        c.2810C\>G              M         Italian            no        37                             5                      yes
  PDB2                                        c.2810C\>G              M         Italian            no        39                             10                     yes
  PDB3                                        c.2810C\>G              F         Italian            no        53                             7                      yes
  PDB4                                        c.2810C\>G              F         French-Canadian    no        61                             2                      NA
  PDB5                                        c.2810C\>G              F         French-Canadian    no        59                             1                      NA

M, female; F, female; PDB, Paget disease of bone; GCT, giant cell tumor of bone; CHD, coronary heart disease; NA, data not available.

Mother and three siblings had PDB, mother also had GCT.

Mother with PDB had either GCT or osteosarcoma.
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